Research Analysts Offer Predictions for FHTX Q1 Earnings

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of Foghorn Therapeutics in a note issued to investors on Thursday, March 13th. B. Riley analyst K. Patel forecasts that the company will post earnings of ($0.34) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. B. Riley also issued estimates for Foghorn Therapeutics’ Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.09) EPS and FY2027 earnings at ($1.34) EPS.

A number of other research firms also recently commented on FHTX. HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Foghorn Therapeutics in a report on Friday, March 7th. Jefferies Financial Group lowered their price target on Foghorn Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a report on Monday, December 16th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $13.17.

Foghorn Therapeutics Stock Up 3.8 %

FHTX stock opened at $4.60 on Monday. The company has a market cap of $255.82 million, a price-to-earnings ratio of -2.40 and a beta of 3.13. The business has a fifty day simple moving average of $4.69 and a 200-day simple moving average of $6.56. Foghorn Therapeutics has a 52 week low of $3.86 and a 52 week high of $10.25.

Foghorn Therapeutics (NASDAQ:FHTX) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.13. The business had revenue of $2.86 million during the quarter, compared to analyst estimates of $8.56 million.

Hedge Funds Weigh In On Foghorn Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Deerfield Management Company L.P. Series C grew its stake in Foghorn Therapeutics by 7.5% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 3,255,514 shares of the company’s stock worth $15,366,000 after purchasing an additional 227,628 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Foghorn Therapeutics during the fourth quarter valued at approximately $9,579,000. Geode Capital Management LLC raised its holdings in Foghorn Therapeutics by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 682,863 shares of the company’s stock worth $3,224,000 after purchasing an additional 5,477 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Foghorn Therapeutics by 58.8% during the fourth quarter. Point72 Asset Management L.P. now owns 634,761 shares of the company’s stock worth $2,996,000 after purchasing an additional 235,059 shares in the last quarter. Finally, State Street Corp raised its holdings in Foghorn Therapeutics by 4.9% during the third quarter. State Street Corp now owns 505,945 shares of the company’s stock worth $4,710,000 after purchasing an additional 23,630 shares in the last quarter. 61.55% of the stock is currently owned by institutional investors and hedge funds.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.